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Abstract
Background: Oocyte in vitro maturation (IVM) and cryopreservation at the time of routine ovarian tissue freezing
may be offered to cancer patients as an additional option for fertility preservation. This study aimed to investigate
the developmental capacity of oocytes isolated from unstimulated ovaries.
Methods: Immature oocytes (n = 63) from seven consenting premenopausal patients were analysed. Oocytes were
collected during routine laparoscopic examination with biopsy of an ovary (cystic adnexal mass, n = 3; cervical
adenocarcinoma, n = 2) or oophorectomy (sex reassignment surgery, n = 2) without previous stimulation of the
ovaries. The stage of the patient’s menstrual cycle was not considered. Oocytes in all visible antral follicles were
aspirated from ovaries, cultured in IVM medium and vitrified at the MII stage before being kept in liquid nitrogen
for at least one month. After warming, oocytes were subjected to parthenogenetic activation by chemical stimulus.
Their further development was recorded at intervals of 24 hours for up to 6 days of culture.
Results: 61.9% of oocytes matured in vitro within 48 hours. The survival rate after vitrification and warming was
61.5%. A total of 75% of surviving oocytes were able to respond to artificial activation, 44.4% of the parthenotes
developed to early embryonic stage. However, only 1 in 18 (5.6%) of the resulting embryos reached blastocyst
stage.
Conclusions: Oocytes matured in vitro from unstimulated ovaries seem to have limited developmental potential
after cryopreservation and artificial activation. Although the outcome of IVM for non-stimulated oocytes is poor, it is
currently the only chance besides cryopreservation of ovarian tissue for women for whom ovarian stimulation is not
possible due to life circumstances. Based on our preliminary results, we suggest that the use of cryopreserved
ovaries for fertility preservation in women with cancer warrants further investigation.
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Background
Fertility preservation in women with cancer is increas-
ingly in demand due to improvements in diagnosis, ef-
fective treatment and follow-up, leading to better patient
survival, especially among younger women [1,2]. The
deleterious effects on ovaries of aggressive chemo- and
radio-therapy are well known. Depending on treatment
regimen, individual circumstances and response to treat-
ment, some patients recover and can lead a normal,
fertile life, while others may suffer permanent loss of go-
nadal function and become sterile [3-5]. Thus, the pre-
servation of reproductive potential in women prior to
treatment for cancer is becoming increasingly important.
Recently, awareness of fertility preservation has also
been raised in women with non-oncological conditions
such as haematological and auto-immunological diseases
that require similar treatments as for cancer. Such treat-
ments can also cause premature ovarian failure or even
total loss of fertility [6].
Currently, one method used to potentially preserve a
woman’s fertility is to freeze ovarian cortical tissue be-
fore the patient undergoes radio- and/or chemotherapy.
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However, depending on the type and stage of cancer—
especially blood-borne cancer and those with potential
danger of metastasis to ovaries—there is a risk of trans-
mission of malignant cells when ovarian cortical tissue is
cryopreserved and later used to restore fertility by auto-
grafting (retransplantation) [7-9]. In the latter situation,
isolation of oocytes from antral follicles at the time of
freezing of the ovarian tissue, with maturation in vitro
before the oocytes are cryopreserved, can be considered
as an alternative approach. However, little is known
about the developmental capacity of such oocytes fol-
lowing cryopreservation and fertilization. This study
therefore aimed to investigate the developmental poten-
tial of oocytes matured in vitro after cryopreservation
and artificial activation by chemical stimulus.
Methods
Between October 2010 and January 2012, seven patients
(age ranged from 18 to 41 years) were recruited at
the Department of Gynecology, University Hospital of
Zurich. Participation was voluntary, and written in-
formed consent was obtained before the procedure.
Inclusion criteria for patient recruitment were a pre-
menopausal status and the feasibility of oocyte retrieval:
all recruited patients were scheduled to undergo a lap-
aroscopic procedure. Medical indications for laparoscopy
were female-to-male sex reassignment surgery (SRS)
(n = 2), benign cystic adnexal mass (n = 3), and cervical
adenocarcinoma (n = 2). In the case of SRS, bilateral
oopherectomy was performed, while in the other cases
an ovarian biopsy was taken. Due to the required me-
dical therapy, the stage of menstrual cycle at the time of
oocyte collection could not be taken into account and
was therefore ignored. In addition, no ovarian stimula-
tion (FSH or HCG priming) was performed in order to
avoid further physical burden to the patients. The two
patients who underwent SRS had preoperative hormonal
treatment with androgens.
Oocyte retrieval
Oocytes were retrieved by biopsy of the ovary. Ex vivo,
visible (size not measured) follicles were aspirated under
reduced pressure of 85 mm Hg using a 19-gauge single-
lumen aspiration needle (K-OPS-7035-RWH-ET; Cook,
Australia), according to the transvaginal aspiration tech-
nique described by Chian et al. [10]. The aspirated fluid
was collected in 10 ml culture tubes containing 2 ml
pre-warmed 0.9% saline solution with 2 IU/ml heparin.
For bilateral oophorectomy, ovaries were transported
immediately in IVM (in vitro maturation) medium
containing HEPES (Sage; CooperSurgical, USA) to the
IVF laboratory (on the same floor of the hospital). Antral
follicles visible on the surface of ovaries were aspirated
using a 1 ml syringe fitted with a 19-gauge needle and
flushed with IVM medium. The collected fluid was exa-
mined for oocyte-cumulus-complex under a stereo-
microscope, and maturity was determined under an
inverted microscope.
In vitro maturation and vitrification
The immature oocytes were cultured in IVM medium
(Sage; CooperSurgical, USA) supplemented with 75
mIU/ml FSH and 75 mIU/ml LH at 37°C in an atmos-
phere of 6% CO2 in air with high humidity for up to
48 hours. About 24 hours after the incubation, the
oocyte-cumulus-complex was denuded with 80 IU/ml
hyaluronidase solution (Vitrolife, Sweden) in order to
assess maturity. Mature oocytes (MII) were vitrified im-
mediately using a Kitazato Vitrification Kit (Japan). Cry-
oTop was used as the carrier. Any immature oocytes
were cultured for an additional 24 hours. Vitrification
was repeated for any further mature oocytes observed.
Oocyte activation and development
Oocytes were kept in liquid nitrogen for at least one
month before being warmed (Kitazato Warming Kit).
Thawed oocytes were allowed to recover for a minimum
of 1 hour at 37°C in a 6% CO2 incubator before being
subjected to artificial activation (parthenogenesis). Only
viable cells were subjected to chemical activation after
warming. For ethical reasons, oocyte activation using
chemical stimulus as described by Polak de Fried et al.
[11] was conducted to simulate the process of ferti-
lization. In brief, oocytes were incubated with 10 μM
ionomycin (Sigma) in G-Mops medium supplemented
with 5% HSA (Vitrolife, Sweden) at 37°C in room air for
6 minutes before placing in culture medium containing
2 mM 6-dimethylamimopurine (6-DMAP, Sigma) for 3 -
hours at 37°C / 6% CO2. The oocytes were analysed for
successful activation 16–20 hours later by assessing the
presence of a single pronucleus within the cytoplasm
without a second polar body. Further development was
recorded at intervals of 24 hours for up to 6 days of
culture.
Statistical evaluation was undertaken using Intercooled
Stata 10.0 (StataCorp LP, College Station, TX) by means
of Fisher’s exact test for categorical data. P-values below
0.05 indicate statistical significance.
The study was reviewed and approved by the Ethics
Committee of Canton Zurich (KEK-ZH-NR: 2010-0169/0).
Results
Table 1 shows the basic characteristics of the oocytes
from the seven patients and summarises the results.
From the seven patients, a total of 63 viable immature
oocytes was obtained, with numbers ranging from 4 to
19 oocytes per patient. At the time of collection, all oo-
cytes were at the germinal vesicle (GV) stage. In total,
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61.9% (39/63) of immature oocytes (GV) reached stage
MII following maturation for up to 48 hours in vitro,
with a rate of 35.9% (14/39) IVM in the first 24 hours.
The survival rate after vitrification and warming was
61.5% (24/39). 75% (18/24) of the surviving oocytes were
able to respond to artificial activation, and 44.4% (8/18)
of them developed to the 4- to 6-cell stage (blastomere).
Only one (1/18, 5.6%) of the resulting embryos (par-
thenotes) reached the blastocyst stage. Analyzing for
different patient diagnosis, no statistically significant dif-
ferences (P=0.269) were found in regard to oocyte devel-
opment (Table 2).
Discussion
Our results show that IVM can be achieved in immature
oocytes isolated from ovaries without taking account of
the phase of the menstrual cycle in which they are col-
lected, and without any hormonal stimulation. There are
some reports on IVM and cryopreservation of immature
oocytes retrieved during routine ovarian tissue cryo-
banking for female patients with cancer, suggesting the
possibility of combined fertility preservation [12-17]. Revel
et al. were the first to demonstrate that, without any hor-
monal stimulation, oocytes retrieved from ovarian tissue
dissection can be matured in vitro and cryopreserved, or
fertilized by ICSI followed by freezing as an additional op-
tion for fertility preservation [12]. However, to our know-
ledge, no report has shown any further investigation of
the fertilization and developmental potential of such oo-
cytes after IVM and cryopreservation.
In our study, we achieved an IVM rate of 61.9%. A
study by Fasano et al. [15] reported a rate of 31% only,
using the same commercial IVM medium and same con-
centrations of gonadotrophin supplements. After vitrifi-
cation and warming, 75% of the surviving oocytes in our
study responded to activation, which is higher than the
expected rate of 67% according to the findings of Paffoni
et al. [18]. Together with the survival rate of 61.5% after
vitrification and warming, our results indicate the
Table 1 Outcomes for oocytes collected from ovaries
Patient Agea No. viable
oocytes
collected
IVM to MII for up










1 18 9 2 1 1 0 Sex
reassignment
surgery
2 24 19 14 10 7 4c Sex
reassignment
surgery
3 25 11 9 4 3 0 Cystic adnexal
mass
4 29 4 2 2 2 2 Cystic adnexal
mass
5 39 5 2 2 1 1 Cystic adnexal
mass
6 37 5 5 4 3 0 Cervical
adenocarcinoma
7 41 10 5 1 1 1 Cervical
adenocarcinoma
Total 63 39/63 (61.9%) 24/39 (61.5%) 18/24 (75%) 8/18 (44.4%) 8/63 (12.7%)
P
valued
0.84 0.53 1.0 0.70
No statistically significant differences were found between different patient diagnosis (SRS, adnexal mass, and adenocarcinoma) at each step (IVM, oocyte
activation and development).
a Age of patient at the time of oocyte collection.
b All MII oocytes were vitrified after IVM.
c One embryo reached the blastocyst stage.
d Fisher’s exact test.
IVM, in vitro maturation; MII, metaphase II.
Table 2 Development of collected oocytes after IVM,








(up to 6 days)
Success
(%)
Sex reassignment surgery 28 4 14.3%
Cystic adnexal mass 20 3 15%
Cervical adenocarcinoma 15 1 6.7%
P value a 0.269
No statistically significant differences were found for further development of
oocytes between the different patient diagnoses.
a Fisher’s exact test.
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development potential of oocytes matured in vitro
followed by cryopreservation and activation. However,
more than half of the activated oocytes in our study
arrested at the pronucleus stage. Nearly all of the divi-
ding parthenotes failed to develop beyond the 6-cell
stage, and only one embryo reached blastocyst stage.
The higher IVM rate in our study may be explained by
the small cohort of seven patients representing a less on-
cologic collective, as some oncologic patients are found
to exhibit impaired potential of oocyte development, al-
though this remains controversial [19].
Using fresh, mature oocytes donated by patients from
controlled ovarian hyperstimulation cycles, Paffoni et al.
have shown that parthenogenetic activation using io-
nomycin and 6-DMAP as chemical stimuli is as effective
as fertilization by ICSI, with 67.3% after activation and
62.3% after fertilization [18]. But these authors also ob-
served that the rate of developmental arrest was signifi-
cantly higher among activated oocytes (32.9%) than among
fertilized oocytes (8.5%), and the blastocyst rate was 12.8%.
Although Polak de Fried et al. have also reported an activa-
tion rate of 86.1% using noninseminated, cryopreserved
human oocytes under similar conditions, the blasto-
cyst rate was 16.7% [11]. Based on these results, we cannot
exclude the possibility that insufficiency of artificial activa-
tion might affect embryo development, causing early
developmental arrest.
The size of dominant follicles at the time of oocyte collec-
tion determines the outcome of in vitro maturation and
embryo development to blastocyst stage [20]. HCG priming
36 hours before oocyte retrieval increases the rate of IVM
and embryo development significantly, resulting in many
live births [21,22]. Since the criteria of patient recruitment
were based mainly on their age (pre-menopausal) and the
feasibility of additional oocyte retrieval, i.e., that the re-
quired surgical procedure would not be compromised, the
stage of the menstrual cycle at the time of oocyte collection
was not considered. This in part reflects the real clinical
situation when dealing with immediate ovarian tissue cryo-
preservation for cancer patients. Thus, while this could
have contributed to the very low rate of blastocyst forma-
tion in our results, our procedure of retrieving oocytes
irrespective of menstrual cycle stage or medical pre-
conditioning reflects the actual clinical situation for cryo-
preservation of ovarian tissue for women with cancer.
The development of oocyte cryopreservation has made
rapid progress since the introduction of vitrification
techniques, and rates of fertilization, development and
implantation have improved significantly, with survival
rates of more than 85% and pregnancy rates of over 40%
[23-25]. It has been further demonstrated that vitrifica-
tion is superior to conventional slow freezing procedures
in terms of meiotic spindle maintenance and recovery
during and after the freezing process [26-28]. Therefore,
in this study we used vitrification to cryopreserve oo-
cytes matured in vitro. The relatively low survival rate of
61.5% could reflect oocyte quality before vitrification.
Since the above-cited results by others were obtained
from either oocyte donation programs or patients seek-
ing fertility treatment, the oocytes were likely to be
healthier than those from the present cohort of diseased
patients in this study. In clinical practice, however, pa-
tients requiring fertility preservation due to cancer-
related diseases are often in a most vulnerable state, as
reflected in our study and also in a recent report by
Escriba et al. [17]. The latter authors found that 36.1% of
the immature oocytes isolated during routine ovarian
tissue cryopreservation for oncology patients achieved
spontaneous nuclear maturation in vitro. However, only
41% of them responded to parthenogenetic activation. It
can be speculated therefore that the outcome of IVM
and oocyte cryopreservation in such cases is less promis-
ing than would be predicted by the results of IVM used
for infertility treatment.
The limitation of our study is the small number of pa-
tients and collected oocytes in this heterogenous patient
collective. However, with the exception of the SRS
group, this might in part reflect the real clinical situation
when dealing with immediate ovarian tissue cryopreser-
vation for cancer patients. We cannot ignore the fact
that pretreatment with androgens for SRS patients might
also have had a negative influence on oocyte quality, al-
though the only blastocyst was generated from one of
the two SRS cases. In addition, no statistically significant
differences were found for the SRS group compared with
the other subject groups in our study. Another limitation
in the current study is that, for ethical reasons, we are
not allowed to perform studies using fertilization. Using
artificial activation only we were not able to reveal the
true developmental potential of oocytes matured in vitro.
An improvement on the study design would be to in-
clude a control group. In theory, a control could consist
of immature oocytes from patients undergoing hormonal
stimulation for IVF. Unfortunately, our daily routine has
shown that these by-products are often in a state of de-
generation, thus limiting their use as a control.
Conclusions
This first attempt suggests that oocytes matured in vitro
from unstimulated ovaries have limited developmen-
tal potential following cryopreservation and artificial ac-
tivation. However, although the outcome of IVM for
non-stimulated oocytes is poor, this method is currently
the only chance besides cryopreservation of ovarian tis-
sue for women for whom time-consuming hormonal
stimulation is not possible due to life circumstances, e.g.
cancer. We hope that our findings will provide a useful
stimulus for further investigation aimed at modifying
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and optimizing the methodology to achieve successful
in vitro culture and development of oocytes isolated
from ovaries during routine ovarian tissue cryopreserva-
tion, particularly from patients with malignant disease.
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